Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
6 evidence topics · 5 sources
Stepped care for GAD: NICE
Monitoring of drug treatment: NICE
Collaborative care in primary care: the CALM trial
“Between June 2006 and April 2008, 1004 primary care patients with PD, GAD, SAD, and/or PTSD were enrolled in the CALM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CALM allowed choice of cognitive behavioral therapy (CBT), medication, or both; included real-time web-based outcomes monitoring to optimize treatment decisions and a computer-assisted program to optimize delivery of CBT by non-expert care managers who also assisted primary care providers in promoting adherence and optimizing medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, response and remission rates (CALM vs. UC) were 63.66% (58.95–68.37) vs. 44.68% (39.76–49.59), and 51.49% (46.60–56.38) vs. 33.28% (28.62–37.93), with a number needed to treat (NNT) of 5.27 (4.18–7.13) for response and 5.5 (4.32–7.55) for remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Collaborative care for anxiety: Cochrane review
“The results also demonstrated significantly greater improvement in anxiety outcomes for adults with anxiety treated with the collaborative care model in the short‐term (SMD ‐0.30, 95% CI ‐0.44 to ‐0.17; RR 1.50, 95% CI 1.21 to 1.87), medium‐term (SMD ‐0.33, 95% CI ‐0.47 to ‐0.19; RR 1.41, 95% CI 1.18 to 1.69), and long‐term (SMD ‐0.20, 95% CI ‐0.34 to ‐0.06; RR 1.26, 95% CI 1.11 to 1.42).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Collaborative care is associated with significant improvement in depression and anxiety outcomes compared with usual care, and represents a useful addition to clinical pathways for adult patients with depression and anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptom-triggered retreatment after a single dose in the DT120 phase 3 trials
Patient, provider, and site support planned by the company
“Referral & Treatment Coordination” (opens the source at this quote in a new tab)
“Treatment-Day Logistics” (opens the source at this quote in a new tab)
“INTEGRATED COMMERCIAL SUPPORT MODEL” (opens the source at this quote in a new tab)
“Connecting patients, providers and sites of care” (opens the source at this quote in a new tab)